A gross comparison of all shared mutations revealed that cancer cell fractions (CCF) increased in recurrent IDH-mutant-noncodel gliomas and decreased in recurrent IDH wild-type glioma, which suggests, respectively, reductions and increases in intra-tumor heterogeneity in recurrent tumors [101]. This evidence concerns the gene IDH2 and central nervous system cancer.